TABLE 1.
Characteristics of Prevaccine and Postvaccine Study Samples From the CDC Cancer Registry Sentinel Surveillance System
| CIN3+ | ICC | |||||||
|---|---|---|---|---|---|---|---|---|
| Prevaccine 1993–2005a | Postvaccine 2014–2015b | Prevaccine 1993–2005c | Postvaccine 2014–2015d | |||||
| Characteristics | (n = 328) | (n = 348) | (n = 777) | (n = 363) | ||||
| Age, y | No. of Patients | % | No. of Patients | % | No. of Patients | % | No. of Patients | % |
| <35e | — | — | — | — | 123 | 15.8 | 96 | 20.5 |
| 15–24 | 162 | 49.4 | 71 | 21.8 | — | — | — | — |
| 25–29 | 108 | 32.9 | 154 | 47.0 | — | — | — | — |
| 30–34 | 58 | 17.7 | 123 | 31.1 | — | — | — | — |
| 35–49 | — | — | — | — | 309 | 39.8 | 134 | 36.1 |
| 50–94 | — | — | — | — | 345 | 44.4 | 133 | 43.4 |
| Race/ethnicity | ||||||||
| Non-Hispanic White | 223 | 83.2 | 195 | 79.0 | 409 | 53.0 | 263 | 70.9 |
| Non-Hispanic Black | 24 | 9.0 | 86 | 17.5 | 129 | 16.7 | 67 | 23.4 |
| Hispanic | 17 | 6.3 | 51 | 2.6 | 124 | 16.1 | 23 | 3.8 |
| Non-Hispanic other races | 4 | 1.5 | 16 | 0.9 | 110 | 14.3 | 10 | 1.8 |
| Missing | 60 | 0 | 5 | 0 | ||||
| Histology | ||||||||
| Squamous cell | 284 | 86.6 | 331 | 95.1 | 570 | 73.4 | 248 | 66.6 |
| Adenocarcinoma | 7 | 2.1 | 11 | 2.8 | 145 | 18.7 | 95 | 27.6 |
| Other | 37 | 11.3 | 6 | 2.1 | 62 | 8.0 | 20 | 5.8 |
| HPV typef | ||||||||
| HPV 16, 18 | 217 | 66.2 | 227 | 67.8 | 517 | 66.5 | 262 | 69.3 |
| HPV 31, 33, 45, 52, 58 | 58 | 17.7 | 83 | 21.7 | 112 | 14.4 | 37 | 10.4 |
| Other oncogenic HPV | 34 | 10.4 | 29 | 7.4 | 50 | 6.4 | 17 | 5.8 |
| Other HPV | 15 | 4.6 | 4 | 1.3 | 25 | 3.2 | 14 | 3.7 |
| HPV negative | 4 | 1.2 | 5 | 1.8 | 73 | 9.4 | 33 | 10.8 |
Abbreviations: CA, Los Angeles County, California; CDC, Centers for Disease Control; CIN3+, cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ; FL, Florida; HI, Hawaii; HPV, human papillomavirus; IA, Iowa; ICC, invasive cervical cancer; KY, Kentucky; LA, Louisiana; MI, Michigan.
The sampling strategy for obtaining cases differed between the prevaccine and postvaccine study; hence, the percentages were not directly comparable. Please refer to the Materials and Methods section for more details. The data source was the CDC Cancer Registry Sentinel Surveillance System.
Cases from cancer registries in IA, CA, and MI; 9.5% of cases diagnosed in 1994, 22.9% in 1995, 34.8% in 2004, and 32.9% in 2005.
Cases from cancer registries in IA, KY, and LA; 47.4% of cases diagnosed in 2014 and 52.6% in 2015. Weighted percentages take into account sampling frame for age and race/ethnicity.
Cases from cancer registries in FL, HI, IA, KY, CA, LA, and MI; 30.1% of cases diagnosed from 1993–2003; 34.4% in 2004, and 35.5% in 2005.
Cases from cancer registries in IA, KY, and LA; 54.8% of cases diagnosed in 2014 and 45.2% in 2015. Weighted percentages take into account sampling frame for age and race/ethnicity.
Minimum age in prevaccine study was 19 y; for the postvaccine study it was 22 y.
Other oncogenic types include HPV 35, 39, 51, 56, 59, 66, and 68.